High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

Slides:

Advertisements

Similar presentations

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

Advertisements

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation.

Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function Cameron.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Early Human Herpesvirus Type 6 Reactivation after Allogeneic Stem Cell Transplantation: A Large-Scale Clinical Study Rémy Dulery, Julia Salleron, Anny.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease Florent Delbos, Walid Barhoumi, Ludovic Cabanne,

Sabina Kersting, Leo F. Verdonck

Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes J. Clausen, M. Enk, B. Vergeiner,

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Betty T. Tran, Abigail Halperin, Jason W. Chien

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.

Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation Mary J. Ninan, Christopher.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Role of the Mycobiome in Human Acute Graft-versus-Host Disease

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Helicobacter pylori Infection and Graft-versus-Host Disease

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal.

Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after.

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation Felix Bahr, Rebekka Wehner, Uwe Platzbecker,

Immune Cell Subset Counts Associated with Graft-versus-Host Disease

Heterogeneous Clearance of Antithymocyte Globulin after CD34+-Selected Allogeneic Hematopoietic Progenitor Cell Transplantation Irina Kakhniashvili,

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus– Positive Patients with Hematologic Disorders: A Report from the Center for.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell.

Possible Impact of Cytomegalovirus-Specific CD8+ T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Mammen Chandy Biology of Blood and Marrow Transplantation

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function Jianqiang Li, Ian Nicoud, Joseph.

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A

Mary Eapen Biology of Blood and Marrow Transplantation

Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment Sascha Dietrich,

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative Disorder Peter J. Podgorny, Alejandra Ugarte-Torres, Yiping Liu, Tyler S. Williamson, James A. Russell, Jan Storek Biology of Blood and Marrow Transplantation Volume 16, Issue 7, Pages 915-926 (July 2010) DOI: 10.1016/j.bbmt.2010.02.027 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Determination of ATG level. (A) Phycoerythrin fluorescence peaks, each corresponding to a standard ATG concentration. X-axis shows phycoerythrin fluorescence intensity area (PE-A). Y-axis shows the percent maximum cell count (of lymphocytes acquired for each ATG concentration). (B) Example of a standard curve. Biology of Blood and Marrow Transplantation 2010 16, 915-926DOI: (10.1016/j.bbmt.2010.02.027) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 ATG levels in patients with selected clinical outcomes. Horizontal bars indicate median values. NNST indicates “not needing systemic therapy” and NST indicates “needing systemic therapy.” P-values shown are from the Mann-Whitney-Wilcoxon rank-sum test (univariate analysis). N.S. indicates nonsignificant or no trend toward significance (P > .15). Biology of Blood and Marrow Transplantation 2010 16, 915-926DOI: (10.1016/j.bbmt.2010.02.027) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 ATG levels in patients with selected clinical outcomes. Horizontal bars indicate median values. NNST indicates “not needing systemic therapy” and NST indicates “needing systemic therapy.” P-values shown are from the Mann-Whitney-Wilcoxon rank-sum test (univariate analysis). N.S. indicates nonsignificant or no trend toward significance (P > .15). Biology of Blood and Marrow Transplantation 2010 16, 915-926DOI: (10.1016/j.bbmt.2010.02.027) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of grade II-IV acute GVHD, chronic GVHD NST or PTLD in patients with day 7 or 28 ATG levels above or below the cutoff specified in Table 2. Solid lines represent patients with ATG levels below the cutoff and broken lines patients with ATG levels above the cutoff. P-values shown are adjusted for covariates (binomial regression multivariate analysis). Biology of Blood and Marrow Transplantation 2010 16, 915-926DOI: (10.1016/j.bbmt.2010.02.027) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions